Mary Haak-Frendscho

Mary Haak-Frendscho

Company: Spotlight Therapeutics

Job title: President, Chief Executive Officer & Board Member


Developing Modular CRISPR-based RNPs to Edit Selected Cell Types In Vivo 11:00 am

• Developing TAGE (Targeted Active Gene Editors), a new class of in vivo cell-targeting CRISPR RNP-based biologics • Applying TAGE to expand the target space in immuno-oncology (IO), as well as for monogenic diseases therapies • IO TAGE, targeting selected immune cells, reprogram the tumor microenvironment to facilitate a systemic anti-tumor responseRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.